The lawsuit asserted that drug companies have a responsibility to show whether antidepressants increase suicidal tendencies in children. It also argued that the companies skew information on their products by not publicizing all the studies conducted on medicines or editing information on published trials. A GlaxoSmithKline spokeswoman, Nancy Pekarek, said the company still feels Mr. Spitzer's civil charge of fraud is unfounded and that the settlement accepts disclosure policies the company had been working on for months, even before Mr. Spitzer's lawsuit was filed. She said the company would try to post data by December 31, 2005, on clinical trials since the company was created in a December 2000 merger. Test results from this week forward will be posted within 10 months of a drug's approval, she said. Mr. Spitzer said GlaxoSmithKline's standard will drive the industry, in part because investors and funders of research will be drawn to a company that is a leader in disclosure of product data.